Skip to main content
SpringerLink
Log in

Trends in Prescription and Determinants of Persistence to Antihypertensive Therapy

The PAPEETE Study

  • Original Research Article
  • Published:
High Blood Pressure & Cardiovascular Prevention Aims and scope Submit manuscript

Abstract

Objectives: To assess trends in prescriptions, determinants and timing of treatment discontinuation and/or changes in antihypertensive drug therapy in a cohort of hypertensive patients living in Pavia, a city in the north of Italy.

Methods: The cohort included 61 493 patients aged ≥18 years who received their first antihypertensive drug prescription (monotherapy, fixed or extemporaneous combination) during the period 2003–6. Patients were classified as ‘persistent’ if 12 months after the beginning of treatment they were still taking a regular therapy (same drug = ‘same therapy users’, added one or more drugs = ‘add-on therapy users’, different drug = ‘switchers’). Otherwise, they were classified as ‘non-persistent’ (stopping therapy after the first prescription = ‘occasional users’; stopping treatment early = ‘stoppers’; taking medicines in an erratic fashion = ‘intermittent users’).

Results: ACE inhibitors were the most frequently prescribed drugs (22.8%), followed by β-adrenoceptor antagonists (β-blockers) [14.3%], diuretics (13.9%), Ca2+ antagonists (11.4%) and angiotensin II type 1 receptor antagonists (angiotensin receptor blockers [ARBs]) [9.3%]. After 12 months, persistent patients were only 11.2% (same therapy users 6.7%, switchers 3.2%, add-on therapy users 1.3%). Non-persistent patients were 88.8% (35.3% occasional users, 20.6% stoppers, 32.8% intermittent users). Patient-related predictors of persistence were older age, male sex, concomitant treatment with antidiabetic and hypolipidaemic drugs and previous hospitalizations for cardiovascular events. Highest level of persistence was seen in patients starting with ARBs (18.8%), followed by ACE inhibitors (11.4%), β-blockers (11.0%), Ca2+ antagonists (10.8%) and diuretics (3.0%). Among ARBs, considering separately monotherapy and fixed-combination therapy, highest level of persistence was observed in patients starting with candesartan, irbesartan, valsartan and telmisartan given in monotherapy, and with valsartan and telmisartan given in fixed-dose combination.

Conclusions: Persistence to antihypertensive treatment at 12 months is only 11.2%, being the lowest with diuretics (3.0%) and the highest with ARBs (18.8%).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Fig. 1.
Table III
Fig. 2.
Fig. 3.
Table IV
Table V
Fig. 4.
Fig. 5.

Similar content being viewed by others

References

  1. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289: 2534–44

    Article  PubMed  CAS  Google Scholar 

  2. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure lowering regimens on major cardiovascular events: second cycle of prospectively designed overviews. Lancet 2003; 362: 1527–35

    Google Scholar 

  3. Chalmers J. Comparison of various blood pressure lowering treatments on the primary prevention of cardiovascular outcomes in recent randomised clinical trials. Clin Exp Hypertens 2004; 26: 709–19

    Article  PubMed  CAS  Google Scholar 

  4. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. BMJ 2008; 336 (7653): 1121–3

    Google Scholar 

  5. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289 (18): 2363–9

    Article  Google Scholar 

  6. Kotseva K, Wood D, De Backer D, et al., for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929–40

    Article  PubMed  Google Scholar 

  7. Eni C, Okonofua EC, Simpson KN, et al. Therapeutic inertia is an impediment to achieving the Healthy People 2010. Blood Pressure Control Goals Hypertens 2006; 47: 345–51

    Google Scholar 

  8. Fujita T, Shimamoto K, Wu Z, et al. What are the major challenges in getting patients to the optimal BP goal? Difficulties in educating doctors and patients. Int J Clin Pract Suppl 2006; 150: 20–2

    Article  Google Scholar 

  9. Costa FV. Compliance with antihypertensive treatment. Clin Exp Hypertens 1996 Apr-May; 18 (3-4): 463–72

    Article  Google Scholar 

  10. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Am J Hypertens 2006; 19: 1190–6

    Article  PubMed  Google Scholar 

  11. Lopatriello S, Berto P, Cramer J, et al. Different aspects of adherence to antihypertensive treatments [abstract]. Expert Rev Pharmacoeconomics Outcomes Res 2004; 4 (3): 317–33

    Article  Google Scholar 

  12. Hyre AD, Krousel-Wood MA, Muntner P, et al. Prevalence and predictors of poor antihypertensive medication adherence in an urban health clinic setting. J Clin Hypertens (Greenwich) 2007 Mar; 9 (3): 179–86

    Google Scholar 

  13. Degli Esposti L, Degli Esposti E, Valpiani G, et al. A retrospective, population-based analysis of persistence with antihypertensive drug therapy in primary care practice in Italy. Clin Ther 2002 Aug; 24 (8): 1347–57

    Article  Google Scholar 

  14. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens 2002; 16: 439–44

    Article  PubMed  CAS  Google Scholar 

  15. Mazzaglia G, Mantovani L, Sturkenboom MC, et al. Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primary care. J Hypertens 2005; 23: 2093–100

    Article  PubMed  CAS  Google Scholar 

  16. Bourgault C, Senecal M, Brisson M, et al. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005 Aug; 19 (8): 607–13

    Article  Google Scholar 

  17. Corrao G, Zambon A, Parodi A, et al. Discontinuation of and changes in drug therapy for hypertension among newly-treated patients: a population-based study in Italy. J Hypertens 2008 Apr; 26 (4): 819–24

    Article  Google Scholar 

  18. Costa FV, D’Ausilio A, Bianchi C, et al. Adherence to antihypertensive medications: a review and update. High Blood Pressure Cardiovasc Prev 2009 Sep; 16 (3): 101–10

    Article  Google Scholar 

  19. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000 Nov-Dec; 3 (6): 417–26

    Article  Google Scholar 

  20. Elliott WJ, Plauschinat CA, Skrepnek GH, et al. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med 2007; 20: 72–80

    Article  PubMed  Google Scholar 

  21. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002; 16: 569–75

    Article  PubMed  CAS  Google Scholar 

  22. Erkens JA, Panneman MM, Klungel OH, et al. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005 Nov; 14 (11): 795–803

    Article  Google Scholar 

  23. Haynes RB, McDonald HP, Garg AX. Helping patients follow prescribed treatment: clinical applications. JAMA 2002; 288: 2880–3

    Article  PubMed  Google Scholar 

  24. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10–7

    Article  PubMed  CAS  Google Scholar 

  25. Kettani FZ, Dragomir A, Côté R et al. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke 2009; 40: 213–20

    Article  PubMed  Google Scholar 

  26. Breekveldt-Postma NS, Penning-van Beest FJA, Siiskonen SJ, et al. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008; 24: 121–7

    PubMed  Google Scholar 

  27. Sokol MC, McGuigan KA, Verbrugge RR, et al. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005; 43: 521–30

    Article  PubMed  Google Scholar 

  28. American Heart Association. High blood pressure 2009 [online]. Available from URL: http://www.americanheart.org/presenter.jhtml?identifier=2139 [Accessed 2009 Sep 15]

  29. Hansson L, Lloyd A, Anderson P, et al. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 2002; 11 (1): 35–45

    Article  Google Scholar 

  30. Gaziano TA, Bitton A, Anand S, et al. The global cost of non optimal blood pressure. J Hypertens 2009; 27: 1472–7

    Article  PubMed  CAS  Google Scholar 

  31. Falaschetti E, Chaudhury M, Mindell J, et al. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension 2009; 53: 480–6

    Article  PubMed  CAS  Google Scholar 

  32. Theodoratou D, Maniadakis N, Fragoulakis V, et al. Analysis of published economic evaluations of angiotensin receptor blockers. Hellenic J Cardiol 2009; 50: 105–18

    PubMed  Google Scholar 

  33. Poluzzi E, Strahinja P, Vargiu A, et al. Initial treatment of hypertension and adherence to therapy in general practice in Italy. Eur J Clin Pharmacol 2005; 61: 603–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This study was funded by Boehringer Ingelheim Italia. For all authors, there is no conflict of interest and there are no persons who contributed to the work who do not meet the criteria for authorship.

Author information

Authors and Affiliations

  1. Madre Fortunata Toniolo Hospital, Bologna, Italy

    Francesco Vittorio Costa

  2. CliCon S.r.l. Health, Economics & Outcomes Research, Via Salara 36, 48100, Ravenna, Italy

    Luca Degli Esposti, Chiara Veronesi & Stefano Buda

  3. Dipartimento Programmazione, Acquisto e Controllo, ASL di Pavia, Pavia, Italy

    Carlo Cerra

Authors
  1. Francesco Vittorio Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luca Degli Esposti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carlo Cerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiara Veronesi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Stefano Buda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luca Degli Esposti.

Additional information

† Population-Based Analysis of PErsistence with Treatment and Economics of TElmisartan Study.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Costa, F.V., Esposti, L.D., Cerra, C. et al. Trends in Prescription and Determinants of Persistence to Antihypertensive Therapy. High Blood Press Cardiovasc Prev 16, 167–176 (2009). https://doi.org/10.2165/11530410-000000000-00000

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11530410-000000000-00000

Keywords

Search

Navigation